Last reviewed · How we verify
Transfusion of rejuvenated and washed autolgous RBCs
Transfusion of rejuvenated and washed autolgous RBCs is a Biologic drug developed by Duke University. It is currently FDA-approved.
At a glance
| Generic name | Transfusion of rejuvenated and washed autolgous RBCs |
|---|---|
| Sponsor | Duke University |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Transfusion of rejuvenated and washed autolgous RBCs CI brief — competitive landscape report
- Transfusion of rejuvenated and washed autolgous RBCs updates RSS · CI watch RSS
- Duke University portfolio CI
Frequently asked questions about Transfusion of rejuvenated and washed autolgous RBCs
What is Transfusion of rejuvenated and washed autolgous RBCs?
Transfusion of rejuvenated and washed autolgous RBCs is a Biologic drug developed by Duke University.
Who makes Transfusion of rejuvenated and washed autolgous RBCs?
Transfusion of rejuvenated and washed autolgous RBCs is developed and marketed by Duke University (see full Duke University pipeline at /company/duke-university).
What development phase is Transfusion of rejuvenated and washed autolgous RBCs in?
Transfusion of rejuvenated and washed autolgous RBCs is FDA-approved (marketed).